# Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

> **NCT02780401** · PHASE1 · COMPLETED · sponsor: **University of Washington** · enrollment: 32 (actual)

## Conditions studied

- HER2/Neu Negative
- No Evidence of Disease
- One or More Positive Axillary Nodes
- Stage IB Breast Cancer
- Stage II Breast Cancer
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer
- Stage III Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
- **BIOLOGICAL:** Sargramostim

## Key facts

- **NCT ID:** NCT02780401
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-02
- **Primary completion:** 2020-10-08
- **Final completion:** 2022-10-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02780401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02780401, "Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02780401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*